🚀 VC round data is live in beta, check it out!
TriSalus Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for TriSalus Life Sciences and similar public comparables like Eurobio Scientific, Senseonics Holdings, Carlsmed, Asterasys and more.
TriSalus Life Sciences Overview
About TriSalus Life Sciences
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Founded
2020
HQ
Employees
110
Website
Financials (LTM)
EV
$300M
TriSalus Life Sciences Financials
TriSalus Life Sciences reported last 12-month revenue of $50M and negative EBITDA of ($13M).
In the same LTM period, TriSalus Life Sciences generated $42M in gross profit, ($13M) in EBITDA losses, and had net loss of ($34M).
Revenue (LTM)
TriSalus Life Sciences P&L
In the most recent fiscal year, TriSalus Life Sciences reported revenue of $45M and EBITDA of ($17M).
TriSalus Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $50M | XXX | $45M | XXX | XXX | XXX |
| Gross Profit | $42M | XXX | $38M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | ($13M) | XXX | ($17M) | XXX | XXX | XXX |
| EBITDA Margin | (26%) | XXX | (37%) | XXX | XXX | XXX |
| EBIT Margin | (46%) | XXX | (58%) | XXX | XXX | XXX |
| Net Profit | ($34M) | XXX | ($39M) | XXX | XXX | XXX |
| Net Margin | (68%) | XXX | (87%) | XXX | XXX | XXX |
| Net Debt | — | — | $13M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TriSalus Life Sciences Stock Performance
TriSalus Life Sciences has current market cap of $286M, and enterprise value of $300M.
Market Cap Evolution
TriSalus Life Sciences' stock price is $4.65.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $300M | $286M | 0.0% | XXX | XXX | XXX | $-0.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTriSalus Life Sciences Valuation Multiples
TriSalus Life Sciences trades at 6.0x EV/Revenue multiple, and (23.5x) EV/EBITDA.
EV / Revenue (LTM)
TriSalus Life Sciences Financial Valuation Multiples
As of April 20, 2026, TriSalus Life Sciences has market cap of $286M and EV of $300M.
Equity research analysts estimate TriSalus Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TriSalus Life Sciences has a P/E ratio of (8.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $286M | XXX | $286M | XXX | XXX | XXX |
| EV (current) | $300M | XXX | $300M | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | (23.5x) | XXX | (18.2x) | XXX | XXX | XXX |
| EV/EBIT | (13.1x) | XXX | (11.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 7.1x | XXX | 7.9x | XXX | XXX | XXX |
| P/E | (8.5x) | XXX | (7.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (15.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TriSalus Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TriSalus Life Sciences Margins & Growth Rates
TriSalus Life Sciences' revenue in the last 12 month grew by 34%.
TriSalus Life Sciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.6M for the same period.
TriSalus Life Sciences' rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TriSalus Life Sciences' rule of X is 75% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
TriSalus Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Margin | (26%) | XXX | (37%) | XXX | XXX | XXX |
| EBITDA Growth | (85%) | XXX | (76%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 75% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 63% | XXX | 64% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 39% | XXX | 48% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 28% | XXX | 33% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 144% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TriSalus Life Sciences Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TriSalus Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Eurobio Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| Senseonics Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Carlsmed | XXX | XXX | XXX | XXX | XXX | XXX |
| Asterasys | XXX | XXX | XXX | XXX | XXX | XXX |
| CapsoVision | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TriSalus Life Sciences M&A Activity
TriSalus Life Sciences acquired XXX companies to date.
Last acquisition by TriSalus Life Sciences was on XXXXXXXX, XXXXX. TriSalus Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TriSalus Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTriSalus Life Sciences Investment Activity
TriSalus Life Sciences invested in XXX companies to date.
TriSalus Life Sciences made its latest investment on XXXXXXXX, XXXXX. TriSalus Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TriSalus Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TriSalus Life Sciences
| When was TriSalus Life Sciences founded? | TriSalus Life Sciences was founded in 2020. |
| Where is TriSalus Life Sciences headquartered? | TriSalus Life Sciences is headquartered in United States. |
| How many employees does TriSalus Life Sciences have? | As of today, TriSalus Life Sciences has over 110 employees. |
| Who is the CEO of TriSalus Life Sciences? | TriSalus Life Sciences' CEO is Mary T. Szela. |
| Is TriSalus Life Sciences publicly listed? | Yes, TriSalus Life Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of TriSalus Life Sciences? | TriSalus Life Sciences trades under TLSI ticker. |
| When did TriSalus Life Sciences go public? | TriSalus Life Sciences went public in 2023. |
| Who are competitors of TriSalus Life Sciences? | TriSalus Life Sciences main competitors are Eurobio Scientific, Senseonics Holdings, Carlsmed, Asterasys. |
| What is the current market cap of TriSalus Life Sciences? | TriSalus Life Sciences' current market cap is $286M. |
| What is the current revenue of TriSalus Life Sciences? | TriSalus Life Sciences' last 12 months revenue is $50M. |
| What is the current revenue growth of TriSalus Life Sciences? | TriSalus Life Sciences revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of TriSalus Life Sciences? | Current revenue multiple of TriSalus Life Sciences is 6.0x. |
| Is TriSalus Life Sciences profitable? | No, TriSalus Life Sciences is not profitable. |
| What is the current EBITDA of TriSalus Life Sciences? | TriSalus Life Sciences has negative EBITDA and is not profitable. |
| What is TriSalus Life Sciences' EBITDA margin? | TriSalus Life Sciences' last 12 months EBITDA margin is (26%). |
| What is the current EV/EBITDA multiple of TriSalus Life Sciences? | Current EBITDA multiple of TriSalus Life Sciences is (23.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.